Version July 2025
Note: Potaba has been discontinued in the United States for >1 year.
Skin conditions:
Oral: Average dose: 12 g/day in 4 to 6 divided doses; may take 2 to 3 months before results are noticeable.
There are no dosage adjustments provided in manufacturer's labeling; use with caution.
There are no dosage adjustments provided in manufacturer's labeling.
Refer to adult dosing.
Skin conditions: Oral: 1 g/10 pounds of weight/day; administer in divided doses.
There are no dosage adjustments provided in manufacturer’s labeling. Use with caution.
There are no dosage adjustments provided in manufacturer’s labeling.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Gastrointestinal: Anorexia, nausea
Miscellaneous: Fever
Postmarketing:
Dermatologic: Skin rash (Meyer-Hoffert 2013)
Hepatic: Hepatotoxicity (including hepatitis, increased liver enzymes, jaundice) (Al Attar 2018, Davies 1967, Roy 2008)
Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Viehweg 2013)
Concurrent use of sulfonamides.
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Concerns related to adverse effects:
• Anorexia: Interrupt therapy if anorexia occurs; may reinstitute once patient improves.
• Nausea: Interrupt therapy if nausea occurs; may reinstitute once patient improves.
Disease-related concerns:
• Diabetes: Use with caution in patients with diabetes mellitus or a history of hypoglycemia.
• Renal impairment: Use with caution in patients with renal impairment.
Potaba has been discontinued in the United States for >1 year.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Capsule, Oral:
Potaba: 500 mg [DSC]
No
Capsules (Potaba Oral)
500 mg (per each): $0.91
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Administer with a glass of water after meals and at bedtime with a snack; also refer to manufacturer’s labeling.
Oral: Administer with a glass of water after meals or with a snack.
Skin conditions: Presently, all indications are classified by the FDA as "possibly effective."
Treatment of scleroderma, dermatomyositis, morphea, linear scleroderma, pemphigus, Peyronie disease.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Sulfonamide Antibiotics: Potassium P-Aminobenzoate may decrease therapeutic effects of Sulfonamide Antibiotics. Risk X: Avoid
Safety for use in pregnancy has not been established.
According to the manufacturer, safety for use in nursing women has not been established.
Take with food to avoid stomach upset.
P-aminobenzoate is a member of the vitamin B complex family. It may have an antifibrotic effect due to increased oxygen uptake at the tissue level.
